122 research outputs found

    Prevalence of peripapillary choroidal neovascular membranes (PPCNV) in an elderly UK population—the Bridlington eye assessment project (BEAP): a cross-sectional study (2002–2006)

    Get PDF
    © 2018, The Royal College of Ophthalmologists. Purpose: There is paucity of data on the epidemiology of peripapillary choroidal neovascularisartion (PPCNV). Our aim was to determine prevalence of PPCNV in the elderly UK population of Bridlington residents aged ≄65 years. Methods: Eyes with PPCNV in the Bridlington eye assessment project (BEAP) database of 3475 participants were analysed. PPCNV outline was drawn, its area measured, and clock-hour involvement of disc circumference recorded. Location and shortest distance from the lesion edge to fovea were recorded. Masked grading for age-related maculopathy (ARM)/reticular pseudodrusen (RPD) within the ETDRS grid was assigned for each eye using a modified Rotterdam scale. Peripapillary retinal pigment epithelial (RPE) changes/drusen were recorded. Visual acuity (VA) and demographic details analysed separately were merged with grading data. Results: PPCNV were identified in ten subjects, and were bilateral in two (20%), a population prevalence of 0.29%, and 0.06% bilaterality. Gender-specific prevalence were 0.36% and 0.19% for females and males, respectively. Age ranged from 66 to 85 years [mean 76.3 (SD 6.4)]. PPCNV were located nasal to disc in 41.7%, measuring 0.46–7.93 mm 2 [mean 2.81 mm 2 (SD 2.82)]. All PPCNV eyes had peripapillary RPE changes. One subject had no ARM, 1 angioid streaks, and 30% RPD. No direct foveal involvement, or reduced VA attributable to PPCNV was observed. Conclusion: PPCNV were infrequent in this population, more common in females, and often located nasal to the disc, without foveal extension. Peripapillary degenerative changes were universal, and strong association with ARM was observed in eyes with PPCNV. Typically, PPCNV were asymptomatic with VA preservation

    Drug Off-Target Effects Predicted Using Structural Analysis in the Context of a Metabolic Network Model

    Get PDF
    Recent advances in structural bioinformatics have enabled the prediction of protein-drug off-targets based on their ligand binding sites. Concurrent developments in systems biology allow for prediction of the functional effects of system perturbations using large-scale network models. Integration of these two capabilities provides a framework for evaluating metabolic drug response phenotypes in silico. This combined approach was applied to investigate the hypertensive side effect of the cholesteryl ester transfer protein inhibitor torcetrapib in the context of human renal function. A metabolic kidney model was generated in which to simulate drug treatment. Causal drug off-targets were predicted that have previously been observed to impact renal function in gene-deficient patients and may play a role in the adverse side effects observed in clinical trials. Genetic risk factors for drug treatment were also predicted that correspond to both characterized and unknown renal metabolic disorders as well as cryptic genetic deficiencies that are not expected to exhibit a renal disorder phenotype except under drug treatment. This study represents a novel integration of structural and systems biology and a first step towards computational systems medicine. The methodology introduced herein has important implications for drug development and personalized medicine

    PsorĂ­ase e o impacto na sexualidade

    Get PDF
    Psoriasis is a skin disease, not contagious, chronic, serious and considered limiting, resulting prejudice, stigma and social exclusion providing loss in quality of life.Mostly affects self-image of affected people, as well as self-esteem and self-concept.These disease characteristics bring great losses in occupational areas, damaging interpersonal relationships of individuals, which may cause impact on various occupational areas, including sexuality, which translates not only as sex itself, but also as identity, social roles, pleasure, reproduction and other. The aim of this study was to investigate the self-image of individuals with psoriasis and their influence on sexuality. This is a qualitative study of a case study with seven patients in the Reference Center, Support and Treatment ParaĂ­ba State Psoriasis installed in the clinic of the University Hospital LauroWanderley – Universidade Federal da ParaĂ­ba. Data were collected through semi-structured interview, categorized and treated according to the Content Analysis. The results show that psoriasis affects the sexuality of individuals, more significantly in women's fashion, as attribute different meanings to the body, for reasons of aesthetics and beauty.Men also feel affected, but in view of the achievement, caring companionship, and seek to clarify their partners or future partners and their relationships, about the disease. We note here the influence of culture to gender conditions.A PsorĂ­ase Ă© uma doença dermatolĂłgica, nĂŁo contagiosa, crĂŽnica, considerada grave e limitante, acarretando preconceito, estigma e exclusĂŁo social proporcionando prejuĂ­zos na qualidade de vida. Na sua grande maioria, afeta a autoimagem das pessoas acometidas, assim como a autoestima e autoconceito. Estas caracterĂ­sticas da doença trazem grandes prejuĂ­zos nas ĂĄreas ocupacionais, prejudicando as relaçÔes interpessoais dos indivĂ­duos, podendo ocasionar impacto em vĂĄrias ĂĄreas ocupacionais, incluindo a sexualidade, que se traduz nĂŁo sĂł como o sexo em si, mas tambĂ©m como identidade, papĂ©is sociais, prazer, reprodução entre outros. O objetivo deste estudo foi investigar sobre a autoimagem dos indivĂ­duos com psorĂ­ase e sua influĂȘncia na sexualidade. Trata-se de um estudo qualitativo do tipo estudo de caso, com sete pacientes do Centro de ReferĂȘncia, Apoio e Tratamento em PsorĂ­ase do Estado da ParaĂ­ba instalado no ambulatĂłrio do Hospital UniversitĂĄrio Lauro Wanderley – Universidade Federal da ParaĂ­ba. Os dados foram coletados por meio de entrevista semiestruturada, categorizados e tratados de acordo com a AnĂĄlise de ConteĂșdo. Os resultados encontrados mostram que a psorĂ­ase afeta a sexualidade dos indivĂ­duos, de forma mais significativa nas mulheres, pois atribuem significados diferentes ao corpo, por razĂ”es de estĂ©tica e beleza. Os homens tambĂ©m se sentem afetados, mas na perspectiva da conquista, se importando com o companheirismo, e procuram esclarecer para suas companheiras ou futuras companheiras e em seus relacionamentos, sobre a doença. Observamos aqui a influĂȘncia da cultura Ă s condiçÔes de gĂȘner

    Loss of C-5 Sterol Desaturase Activity Results in Increased Resistance to Azole and Echinocandin Antifungals in a Clinical Isolate of Candida parapsilosis

    Get PDF
    Among emerging non-albicans Candida species, Candida parapsilosis is of particular concern as a cause of nosocomial bloodstream infections in neonatal and intensive care unit patients. While fluconazole and echinocandins are considered effective treatments for such infections, recent reports of fluconazole and echinocandin resistance in C. parapsilosis indicate a growing problem. The present study describes a novel mechanism of antifungal resistance in this organism affecting susceptibility to azole and echinocandin antifungals in a clinical isolate obtained from a patient with prosthetic valve endocarditis. Transcriptome analysis indicated differential expression of several genes in the resistant isolate, including upregulation of ergosterol biosynthesis pathway genes ERG2, ERG5, ERG6, ERG11, ERG24, ERG25, and UPC2. Whole-genome sequencing revealed that the resistant isolate possessed an ERG3 mutation resulting in a G111R amino acid substitution. Sterol profiles indicated a reduction in sterol desaturase activity as a result of this mutation. Replacement of both mutant alleles in the resistant isolate with the susceptible isolate's allele restored wild-type susceptibility to all azoles and echinocandins tested. Disruption of ERG3 in the susceptible and resistant isolates resulted in a loss of sterol desaturase activity, high-level azole resistance, and an echinocandin-intermediate to -resistant phenotype. While disruption of ERG3 in C. albicans resulted in azole resistance, echinocandin MICs, while elevated, remained within the susceptible range. This work demonstrates that the G111R substitution in Erg3 is wholly responsible for the altered azole and echinocandin susceptibilities observed in this C. parapsilosis isolate and is the first report of an ERG3 mutation influencing susceptibility to the echinocandins

    Rivaroxaban Compared with Standard Anticoagulants for the Treatment of Acute Venous Thromboembolism in Children: a Randomised, Controlled, Phase 3 Trial

    Full text link
    Background: Treatment of venous thromboembolism in children is based on data obtained in adults with little direct documentation of its efficacy and safety in children. The aim of our study was to compare the efficacy and safety of rivaroxaban versus standard anticoagulants in children with venous thromboembolism. Methods: In a multicentre, parallel-group, open-label, randomised study, children (aged 0–17 years) attending 107 paediatric hospitals in 28 countries with documented acute venous thromboembolism who had started heparinisation were assigned (2:1) to bodyweight-adjusted rivaroxaban (tablets or suspension) in a 20-mg equivalent dose or standard anticoagulants (heparin or switched to vitamin K antagonist). Randomisation was stratified by age and venous thromboembolism site. The main treatment period was 3 months (1 month in children <2 years of age with catheter-related venous thromboembolism). The primary efficacy outcome, symptomatic recurrent venous thromboembolism (assessed by intention-to-treat), and the principal safety outcome, major or clinically relevant non-major bleeding (assessed in participants who received ≄1 dose), were centrally assessed by investigators who were unaware of treatment assignment. Repeat imaging was obtained at the end of the main treatment period and compared with baseline imaging tests. This trial is registered with ClinicalTrials.gov, number NCT02234843 and has been completed. Findings: From Nov 14, 2014, to Sept 28, 2018, 500 (96%) of the 520 children screened for eligibility were enrolled. After a median follow-up of 91 days (IQR 87–95) in children who had a study treatment period of 3 months (n=463) and 31 days (IQR 29–35) in children who had a study treatment period of 1 month (n=37), symptomatic recurrent venous thromboembolism occurred in four (1%) of 335 children receiving rivaroxaban and five (3%) of 165 receiving standard anticoagulants (hazard ratio [HR] 0·40, 95% CI 0·11–1·41). Repeat imaging showed an improved effect of rivaroxaban on thrombotic burden as compared with standard anticoagulants (p=0·012). Major or clinically relevant non-major bleeding in participants who received ≄1 dose occurred in ten (3%) of 329 children (all non-major) receiving rivaroxaban and in three (2%) of 162 children (two major and one non-major) receiving standard anticoagulants (HR 1·58, 95% CI 0·51–6·27). Absolute and relative efficacy and safety estimates of rivaroxaban versus standard anticoagulation estimates were similar to those in rivaroxaban studies in adults. There were no treatment-related deaths. Interpretation: In children with acute venous thromboembolism, treatment with rivaroxaban resulted in a similarly low recurrence risk and reduced thrombotic burden without increased bleeding, as compared with standard anticoagulants. Funding: Bayer AG and Janssen Research & Development. © 2020 Elsevier Ltd

    Prise en charge des voies aĂ©riennes – 1re partie – Recommandations lorsque des difficultĂ©s sont constatĂ©es chez le patient inconscient/anesthĂ©siĂ©

    Get PDF
    • 

    corecore